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The present single center prospective phase II clinical trial is designed to evaluate the eﬃcacy and 
safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases.  Patients who have 
colorectal lung metastases without extrapulmonary metastases are included in this study.  The primary 
endpoint is 3-year overall survival (OS) after RF ablation.  The secondary endpoints are the prevalence 
of adverse events within 4 weeks,  local tumor progression rate,  1- and 5-year OS,  cause-speciﬁc sur-
vival,  and relapse-free survival.  The recruitment of patients commenced in July 2014,  and the enrol-
ment of 45 patients is intended over the 3 years of study period.
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C olorectal cancer (CRC) is one of the most com-mon cancers globally [1].  Approximately 608,000 
deaths (8  of all cancer deaths) associated with CRC 
are estimated rendering it the fourth most common 
cause of death from cancer.  As previously described,  
metastatic disease develops in 50  of patients with 
CRC [2].  Pulmonary metastasis develops in 5 to 15  
of CRC patients,  and surgical resection of the meta-
static tumor has been accepted as a potentially cura-
tive intervention for such patients [3-7].  While video-
assisted thoracic surgery as a less invasive intervention 
is becoming widespread,  poor pulmonary function or 
extrapulmonary comorbidities may hinder the surgical 
intervention.  In addition,  according to the large-scale 
retrospective surveillance of curative resection for the 
treatment of CRC in Japan,  pulmonary metastasec-
tomy has been employed for the treatment of 38  of 
patients [8].
　 Recently,  several retrospective studies have indi-
cated the safety,  feasibility,  and promising anticancer 
eﬀect of radiofrequency (RF) ablation as an alterna-
tive option for patients with unresectable pulmonary 
metastases post-surgery [9-11].  However,  the afore-
mentioned studies were designed as retrospective 
observational studies,  and an assessment of the 
hypothesis with regard to the outcomes of patients 
treated with RF ablation for colorectal lung metasta-
ses has not been performed.  In view of the notion that 
RF ablation is less invasive than surgical resection,  
and thus may be a promising alternative,  the prospec-
tive evaluation of its eﬀectiveness is warranted.  
Acta Med.  Okayama,  2016
Vol.  70,  No.  4,  pp.  317-321
CopyrightⒸ 2016 by Okayama University Medical School.
Clinical Study Protocol http ://escholarship.lib.okayama-u.ac.jp/amo/
Received June 13,  2016 ; accepted July 13,  2016.
＊Corresponding author.  Phone : ＋81-86-235-6510; Fax : ＋81-86-235-6505
E-mail : sakurai-jun@okayama-u.ac.jp (J. Sakurai)
Conﬂict of Interest Disclosures: No potential conﬂict of interest relevant 
to this article was reported.
Based on the previous retrospective studies,  we 
hypothesized that the outcomes of treatment with RF 
ablation are comparable to those of the surgical 
metastasectomy.
　 Based upon this hypothesis,  we intend to conduct 
the present study in order to evaluate the eﬃcacy and 
safety of RF ablation therapy for the treatment of 
colorectal lung metastases.  Herein,  we present a 
detailed protocol for this prospective phase II clinical 
trial.
Endpoints
　 Purpose. The primary objective of this study is 
to evaluate the eﬀectiveness of lung RF ablation,  as 
indicated by the 3-year overall survival (OS),  in 
patients with pulmonary metastases from CRC at our 
institution.
　 Study Design. The present study is a single-
center,  single-arm,  prospective,  open-label phase II 
clinical trial.  The study protocol has been approved 
by Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences and Okayama 
University Hospital,  Ethics Committe (m29005).  In 
addition,  this study is registered at the University 
Hospital Medical Information Network (UMIN),  
Japan (Trial registration number: 000014391).
　 Endpoints. The primary endpoint is the 3-year 
OS.  OS time is deﬁned as the time from registration 
date to death from any cause,  and will be censored at 
the last follow-up date if the patient is alive.  
Furthermore,  3-year OS is evaluated for the patients 
who meet eligibility criteria and are performed lung 
RF ablation in compliance with the protocol.
　 The secondary endpoints are as follows; (1) the 
prevalence and severity of adverse events (AEs) 
within 4 weeks of the procedure,  (2) the local tumor 
progression rate,  (3) 1- and 5-year OS,  (4) cause-
speciﬁc survival (CSS),  and (5) recurrent-free sur-
vival (RFS).
　 The prevalence of AEs at 4-weeks is to be deﬁned 
as the proportion of patients display AEs within 4 of 
undergoing.  Severe adverse event (SAE) is deﬁned as 
an AE that poses a signiﬁcant hazard or side eﬀect,  
regardless of the investigatorʼs opinion on the relation-
ship to the RF ablation system product.  It includes,  
but is not limited to,  any event that is fatal,  life-
threatening,  requires or prolongs inpatient hospital-
ization,  causes a persistent or signiﬁcant disability or 
incapacity,  or is considered an important medical 
event.  The severity of the AEs is classiﬁed based on 
the Common Terminology Criteria for Adverse Events 
version.  4.0.
　 The local tumor progression is deﬁned as the cir-
cumferential enlargement of the target lesion,  the 
appearance of irregular,  scattered,  nodular,  or 
eccentric foci,  which is measurable by contrast-
enhanced CT (3,  6,  9,  12 and every 6 months after 
the RF ablation).  The local tumor progression rate is 
deﬁned as a proportion of the local tumor recurrence 
for all the target lesions.
　 The CSS time is deﬁned as the number of days 
from the registration date to death related to CRC 
progression.  The RFS time is deﬁned as the time 
from the registration date to the earliest date between 
that of the diagnosis of local tumor progression or the 
death of the patient from any cause.  Each CSS and 
RFS time will be censored at the last follow-up date if 
the patient is alive.
　 Primary hypothesis and statistical sample 
size calculation. This study has been designed to 
compare the OS after the use of RF ablation for the 
treatment of pulmonary metastases to a target perfor-
mance goal.  The estimated 3-year OS after RF abla-
tion for pulmonary metastases is approximately 50  
(46-57 ) based on the previous retrospective studies 
[11-16],  which is comparable to that of patients 
treated with pulmonary metastasectomy (60 ) [3-7],  
and is considered the performance goal of this phase 




where PT is the anticipated 3-year OS after RF abla-
tion.  The use of RF ablation for the treatment of 
pulmonary metastases will be considered eﬀective if 
the results of the present study verify that the lower 
limit of the one-sided 95  conﬁdence interval for PT 
is above 50 .  We did not have relevant data regard-
ing the additional expected eﬀect of RF ablation for 
colorectal lung metastases,  so instead simply assumed 
that a 20  or more decrease in 3-year OS,  i.e.,  
3-year OS threshold of 30 ,  would be clinically 
meaningless.  Against this background,  39 patients in 
total would provide a statistical power of 80  to test 
the primary hypothesis at the one-sided signiﬁcance 
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level of 0.05.  Thus,  the planned sample size is 45 
patients,  including the subjects who are excluded from 
the analyses because of protocol violation or patient 
withdrawal from the study prior to evaluation of pri-
mary endpoint.
　 Investigation of change in pulmonary func︲
tion and predictive biomarkers. To investigate 
the change in pulmonary function after the administra-
tion of RF ablation,  vital capacity and forced expira-
tory volume in one second (FEV1) at 4 weeks will be 
measured for all the patients.  In addition,  the predic-
tive biomarkers,  including gene mutation and microR-
NAs for the survival after RFA will be investigated in 
detail.  Such biomarkers may be useful to determine 
suitable candidates for RF ablation preoperatively.
Eligibility Criteria
　 Inclusion criteria. 1) Patients with CRC in 
whom the primary lesion is controlled and the pulmo-
nary metastasis is diagnosed clinically and radiologi-
cally without any viable extrapulmonary metastases.  
2) All pulmonary target lesions are considered to be 
treatable with RF ablation.  3) The number of target 
lesions are less than 6 in total,  and the long axis 
diameter of each lesion is less than 3.0cm.  4) Major 
organ function is normal based on the blood,  bio-
chemical,  and pulmonary function tests as follows:
a,  White blood-cell count 3,000/µL; b,  Platelet count 
50,000/µL; c,  Hemoglobin 7.5g/dL; d,  Serum total 
bilirubin 2.0mg/dL; e,  Serum creatinine 2.0mg/
dL; f,  PT-INR 1.5; g,  FEV1 1.0L.
　 Exclusion criteria. 1) Absence of safe needle 
insertion pathway.  2) RF ablation is considered to be 
hazardous because of critical organs in proximity to 
the target lesion.  3) The patient has more than one of 
the severe comorbidities as follows:
a.  Severe heart failure (New York Heart Association 
[NYHA] Classiﬁcation III or IV); b.  Progressive 
inﬂammation or infectious disease except viral hepati-
tis.  4) The presence of other uncontrollable malignant 
tumors.  5) Peritoneal dissemination and/or malignant 
ascites.  6) The patient has a fever higher than 38℃ 
before the RF ablation.  7) Severe impairment of 
contralateral pulmonary function.  8) Presence of pul-
monary hypertension.  9) Presence of interstitial 
pneumonia.  10) Usage of antiplatelet agent,  antico-
agulant,  or thrombolytic agent that cannot be ceased 
temporarily during the perioperative period.  11) The 
patient is or may have a potential to be pregnant.  12) 
The patient is regarded as inappropriate for being 
enrolled into the study by physicians.
Treatment Methods
　 Radiofrequency ablation procedure. Written 
informed consent for RF ablation is obtained from the 
patient.  The RF ablation procedure will be performed 
percutaneously under the guidance of CT ﬂuoroscopy.  
Intraprocedural pain will be treated by using a combi-
nation of local anesthesia and intravenous administra-
tion of fentanyl or local plus epidural anesthesia.  
Under local anesthesia,  a 17-gauge multitined expand-
able electrode with arrays (LeVeen,  Boston Scientiﬁc,  
MA,  USA) or a single internally-cooled electrode 
(Cool-tip RF needle,  Medtronic,  MN,  USA) will be 
introduced into the target lesions percutaneously.  
Each electrode is connected to RF generator (RF 
3000; Boston Scientiﬁc,  or Cool-tip RF generator;  
Medtronic).
　 In the case of the Boston Scientiﬁc device,  the RF 
energy is applied by increasing the RF power in incre-
mental steps until a noticeable increase is observed in 
the impedance or automatic shut-oﬀ occurred at 
15min; this is repeated once at each site.  Further to 
this,  repositioning of the electrode for multiple over-
lapping ablations is performed.  When using the 
Medtronic device,  radiofrequency energy is applied 
with an impedance control algorithm for 12 minutes 
during internal cooling of the electrode.  Thereafter,  
the temperature is measured at the electrode tip; if it 
does not reach 60℃,  another energy application is 
performed at the same site (see Appendix).
　 Immediately after the procedure,  a CT scan of the 
entire thorax will be performed to evaluate the pres-
ence of AEs and ground-glass attenuation (GGA),  
which indicates the ablation zone,  surrounding the 
target lesions.  Further to this,  an upright posteroan-
terior chest radiograph will be obtained 4 hours after 
the procedure and repeated the following morning to 
evaluate the presence of any early AEs.  The charac-
teristics of the target lesion,  the ablation protocol for 
each patient,  and the AEs after the procedure will be 
recorded on the case report form.
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Statistical Consideration
　 Interim analysis and monitoring. Neither an 
interim analysis nor in-house monitoring is planned to 
be performed during the study period.  The Data and 
Safety Monitoring Committee independently reviews 
the reports of SAEs,  and if present,  may decide on 
the early termination of this study.
　 Statistical analysis. Clinical data obtained in 
this study will be summarized by descriptive statistics.  
OS,  CSS,  and RFS will be estimated using the Kaplan-
Meier method.  If the lower limit of the 95  conﬁ-
dence interval for 3-year OS is greater than 50 ,  the 
null hypothesis for eﬀectiveness will be rejected in 
favor of the alternative hypothesis.
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　 Appendix. Algorithm of Radiofrequency Ablation 
for Pulmonary Metastases from Colorectal Cancer
　 1.  Selection of the RF needle.  The length of the 
non-insulated active-tip or the diameter of expandable 
tines should be at least 10mm longer than the long-axis 
diameter of the tumor.  However,  a needle with a 
shorter,  non-insulated active-tip or expandable tines 
can be used when there is a high risk of injury to the 
thoracic wall,  mediastinum,  or large vessels.
　 2.  Application algorithm
　 (1) LeVeen system.  RF energy is applied with an 
impedance control algorithm.  In general,  RF applica-
tion will be performed twice per needle position.  The 
RF power is increased with time according to the 
algorithm shown in Table 1.  The RF energy for 1 RF 
application is up to 190W.  The maximum duration for 
1 RF application is 15 min.
　 When the automatic shut-oﬀ (“roll-oﬀ”) is observed,  
the second RF power is set to half of the ﬁrst maxi-
mum RF power.
　 If the automatic shut-oﬀ is not observed,  repeat RF 
application with the last maximum RF power is per-
formed 30 sec after the end of the ﬁrst application.
　 (2) Cool-tip system.  RF energy is applied with an 
impedance control algorithm for 12 min per needle 
position during internal cooling of the electrode.  The 
RF power is increased with time according to the 
algorithm shown in Table 2.  The RF energy for 1 RF 
application is up to 140W.
　 When the automatic shut-oﬀ (“break down”) is 
observed,  the RF application is restarted and contin-
ued until a total application time of 12 min.  The sec-
ond RF power is then set to half of that of the ﬁrst 
maximum RF power.
　 If the automatic shut-oﬀ is not observed,  or the 
temperature of the active tip is less than 60℃ after 
RF application for 12 min,  additional RF application 
may be performed with the documentation of the cause 
of the additional RF application in the case report 
form.
　 3.  Overlapping procedure.  Overlapping ablation 
can be performed to achieve the entire coverage of the 
tumor with an ablative margin＞5mm.
Table 1　 RF application algorithm for LeVeen system
Expandable tines 2cm 3cm 3.5cm 4cm
Initial RF power 10W 20W 30W 40W
Rate of increase 5W/min 5W/min 10W/min 10W/min
Table 2　 RF application algorithm for Cool-tip system
2cm active tip 3cm active tip
Initial RF power 30 or 40W 40 or 50 or 60W
Rate of increase 10W/min 10W/min
